Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis
- PMID: 16917107
- DOI: 10.1161/01.ATV.0000241589.52950.4c
Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis
Abstract
Objective: Hypofibrinolysis promotes atherosclerosis progression and recurrent ischemic events in premature coronary artery disease. We investigated the role of fibrin physical properties in this particular setting.
Methods and results: Biomarkers of recurrent thrombosis and premature coronary artery disease (CAD) were measured in 33 young post-myocardial infarction patients with angiographic-proven CAD and in 33 healthy volunteers matched for age and sex. Ex vivo plasma fibrin physical properties were assessed by measuring fibrin rigidity and fibrin morphological properties using a torsion pendulum and optical confocal microscopy. The fibrinolysis rate was derived from continuous monitoring of the viscoelastic properties after addition of lytic enzymes. Young CAD patients had a significant increase in plasma concentration of fibrinogen, von Willebrand factor, plasminogen activator inhibitor type 1, and lipoprotein(a) as compared with controls (P<0.05). Fibrin of young CAD patients was stiffer (P=0.002), made of numerous (P=0.002) and shorter fibers (P=0.04), and lysed at a slower rate than that of controls (P=0.03). Fibrin stiffness was an independent predictor for both premature CAD and hypofibrinolysis.
Conclusions: This first detailed study of clot properties in such a group of patients demonstrated that abnormal plasma fibrin architecture is an important feature of both premature CAD and fibrinolysis rate. The determinants of this particular phenotype warrant further investigation.
Comment in
-
Fibrin gel architecture influences endogenous fibrinolysis and may promote coronary artery disease.Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2419-20. doi: 10.1161/01.ATV.0000245798.26855.88. Arterioscler Thromb Vasc Biol. 2006. PMID: 17053173 Review. No abstract available.
Similar articles
-
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.Thromb Haemost. 2014 Dec;112(6):1142-50. doi: 10.1160/TH14-05-0468. Epub 2014 Sep 4. Thromb Haemost. 2014. PMID: 25187394
-
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.Arterioscler Thromb Vasc Biol. 2000 May;20(5):1354-61. doi: 10.1161/01.atv.20.5.1354. Arterioscler Thromb Vasc Biol. 2000. PMID: 10807754
-
Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease.Blood Coagul Fibrinolysis. 2016 Jun;27(4):401-7. doi: 10.1097/MBC.0000000000000462. Blood Coagul Fibrinolysis. 2016. PMID: 26650459
-
Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease.Biomolecules. 2021 Jul 15;11(7):1036. doi: 10.3390/biom11071036. Biomolecules. 2021. PMID: 34356659 Free PMC article. Review.
-
The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.Dan Med Bull. 1990 Jun;37(3):210-34. Dan Med Bull. 1990. PMID: 2192835 Review.
Cited by
-
Mechanisms of fibrin polymerization and clinical implications.Blood. 2013 Mar 7;121(10):1712-9. doi: 10.1182/blood-2012-09-306639. Epub 2013 Jan 10. Blood. 2013. PMID: 23305734 Free PMC article. Review.
-
Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.PLoS One. 2012;7(4):e35690. doi: 10.1371/journal.pone.0035690. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536427 Free PMC article.
-
Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease.PLoS One. 2022 Oct 27;17(10):e0275956. doi: 10.1371/journal.pone.0275956. eCollection 2022. PLoS One. 2022. PMID: 36301961 Free PMC article. Clinical Trial.
-
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.J Thromb Thrombolysis. 2020 Feb;49(2):192-198. doi: 10.1007/s11239-019-02014-5. J Thromb Thrombolysis. 2020. PMID: 31872349 Free PMC article. Clinical Trial.
-
Pathophysiologic and Therapeutic Perspectives Based on Thrombus Histology in Stroke.J Stroke. 2020 Jan;22(1):64-75. doi: 10.5853/jos.2019.03440. Epub 2020 Jan 31. J Stroke. 2020. PMID: 32027792 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous